Immuno-Oncology Stocks Q4 In Review: Exact Sciences (NASDAQ:EXAS) Vs Peers [Yahoo! Finance]
JAMA Oncology Publication Strengthens Evidence for Oncotype DX® Test Reliability Across Racial and Ethnic Groups [Yahoo! Finance]
JAMA Oncology Publication Strengthens Evidence for Oncotype DX® Test Reliability Across Racial and Ethnic Groups
Exact Sciences Co. (NASDAQ: EXAS) had its "buy" rating re-affirmed by analysts at Guggenheim. They now have a $60.00 price target on the stock.
Exact Sciences Co. (NASDAQ: EXAS) was upgraded by analysts at Mizuho to a "strong-buy" rating.